The Niche Episode 034 – Genentech, GSK, BMS, Cassava, Sanofi, Hyperfine

Genentech’s next tech, GSK divests to invest, Bristol Myers Squibb checks oncology, Cassava Sciences raises capital, Libtayo gets expanded FDA approval, and Hyperfine turns on hyperdrive. 

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-34-1
https://tinyurl.com/Niche-34-2
https://tinyurl.com/Niche-34-3
https://tinyurl.com/Niche-34-4
https://tinyurl.com/Niche-34-5
https://tinyurl.com/Niche-34-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 033 – Merck 3x, Parexel, NeoGenomics, 23andMe, Revolution Medicine, and Sana

Two Mercks – three stories, Paraxel gets genomes, Genomes get Money, and 2021 is the year of the upsized public offering.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-33-Merck1
https://tinyurl.com/Niche-33-Merck2
https://tinyurl.com/Niche-33-Merck3
https://tinyurl.com/Niche-33-2
https://tinyurl.com/Niche-33-3
https://tinyurl.com/Niche-33-4
https://tinyurl.com/Niche-33-5
https://tinyurl.com/Niche-33-6 

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 032 – Biogen, Aurinia, Senseonics, Novavax, and J&J

Biogen gets punted but it’s good, lupus breakthroughs, Senseonics raises capital, and Novavax and Johnson & Johnson… and Janssen.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-032-1
https://tinyurl.com/Niche-032-2
https://tinyurl.com/Niche-032-3
https://tinyurl.com/Niche-032-4
https://tinyurl.com/Niche-032-5

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 031 – (Bonus) Interview with John Reites CEO of Thread Research

This is our January interview bonus. I sit down with John Reites, founder and CEO of Thread Research to discuss eCOA, decentralized clinical trials past, present, and future, and how you can think about a decentralized approach to your project.

 
Timeline

1:00 – The last 10 years of decentralized research

3:15 – The current regulatory landscape and variability in the industry

5:32 – Moving into the life sciences from another spaces 

8:28 – Breakdown of eCOA and the subcategories you need to know about 

12:36 – Are all trials becoming decentralized? 

15:40 – Decentralized trials in the future

22:04 – Data Security with eCOA and decentralized trials   

25:58 – Challenges implementing international and multinational decentralized trials 

32:00 – Steps you should take to make your trial decentralized-ready 

Sponsors
https://www.thescopemethod.com

More on John Reites
https://www.threadresearch.com

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 030 – Thermo Fisher Scientific, Boston Scientific, Verve, and Vera

Thermo Fisher Scientific spends a billion, Boston Scientific also spends a billion and gets FDA approval, Verve pulls $94 million for CRISPR in humans, and Vera raises $80 million for Berger’s disease

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche030-1
https://tinyurl.com/Niche030-2
https://tinyurl.com/Niche030-3
https://tinyurl.com/Niche030-4

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 029 – 100m, EvoQ + Amgen, Merck, Noctrix, Delfi

100 million vaccines, EvoQ’s NanoDisk, Merck gets FDA priority, and startups in wearables, startups in diagnostics.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche029-1
https://tinyurl.com/Niche029-2
https://tinyurl.com/Niche029-3
https://tinyurl.com/Niche029-4

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.